Therapeutic experience with azathioprine in psoriasis
Mezzadra, G.; Randazzo, S.D.; Mirone, A.
Giornale Italiano di Dermatolotia. Minerva Dermatologica 47(2): 72-76
1972
ISSN/ISBN: 0300-1318 PMID: 5067555 Document Number: 49402
Document emailed within 1 workday
Related Documents
Feldges, D.H.; Barnes, C.G. 1976: Treatment of psoriasis arthropathy with either azathioprine or methotrexate Schweizerische Rundschau für Medizin Praxis 65(21): 652-654Griffiths, C.E. 1998: Novel therapeutic approaches to psoriasis Hospital Medicine 59(7): 539-542
Medzihradsky, J.L.; Klein, C.; Elion, G.B. 1982: Differential interference by azathioprine and 6-mercaptopurine with antibody-mediated immunoregulation: synergism of azathioprine and antibody in the control of an immune response Journal of Immunology 129(1): 145-149
Braun-Falco, O.; Hofmann, C.; Plewig, G. 1978: Photochemotherapy, a new therapeutic method in psoriasis Minerva Medica 69(41): 2773-2775
Greiner, J.; Miehe, M.; Weber, H.; Stoimenov, A.; Sönnichsen, N.; Diezel, W. 1990: Therapeutic use of splenopentin (DA SP-5) in patients with psoriasis arthropathica Dermatologische Monatschrift 176(2-3): 157-162
Koo, J. 1998: Therapeutic options for psoriasis: Review and update Saudi Medical Journal 19(3): 232-236
Lhermitte, F.; Marteau, R.; de Saxcé, H. 1987: Treatment of progressive and severe forms of multiple sclerosis using a combination of antilymphocyte serum, azathioprine and prednisone. Clinical and biological results. Comparison with a control group treated with azathioprine and prednisone only. 4-year follow-up Revue Neurologique (Paris) 143(2): 98-107
Ortonne, J.P. 2005: Therapeutic management of plaque psoriasis: the interest of anti-TNFalpha Annales de Dermatologie et de Venereologie 132(8-9 Pt 2: 4s6-4s9
Ieiri, I.; Nakayama, J.; Murakami, H.; Hori, Y.; Higuchi, S. 1996: Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis International Journal of Clinical Pharmacology and Therapeutics 34(3): 106-111
Mudigonda, T.; Dabade, T.S.; West, C.E.; Feldman, S.R. 2012: Therapeutic modalities for localized psoriasis: 308-nm UVB excimer laser versus nontargeted phototherapy Cutis 90(3): 149-154
Monfrecola, G.; Mangone, S.; Procaccini, E.M.; Santoianni, P. 1988: Topical administration of hematoporphyrin derivative and red light irradiation. a therapeutic approach in psoriasis Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale Societa Italiana di Dermatologia e Sifilografia 123(12): 671-674
Baros, D.N.ć; Gajanin, V.S.; Gajanin, R.B.; Zrnić, B. 2014: Comparative analysis of success of psoriasis treatment with standard therapeutic modalities and balneotherapy Medicinski Pregled 67(5-6): 154-160
Mashkilleĭson, A.L.; Golousenko, I.I. 1989: Experience in treating psoriasis patients with the preparation Ditrastic Vestnik Dermatologii i Venerologii 12: 51-52
Gajardo, J. 1989: Clinical experience with etretinate (Tigason) in 26 patients with psoriasis Revista Medica de Chile 117(5): 516-522
Ardigò, M.; Giuliani, A.; de Felice, C.; Mastroianni, A.; Berardesca, E. 2008: Efficacy of adalimumab in plaque psoriasis: experience on 28 patients Journal of Drugs in Dermatology: Jdd 7(10): 935-939
Hofmann, C.; Plewig, G.; Braun-Falco, O. 1976: Clinical experience with the 8-methoxypsoralen-UVA therapy (photochemotherapy) of psoriasis Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 27(12): 588-594
Muller, S.A.; Perry, H.O. 1984: The Goeckerman treatment in psoriasis: six decades of experience at the Mayo Clinic Cutis 34(3): 265-8 270
Pullmann, H.; Wichmann, A.C.; Steigleder, G.K. 1978: Practical experience with various forms of phototherapy in psoriasis--PUVA-, SUP-, tar-UVitherapy Zeitschrift für Hautkrankheiten 53(18): 641-647
Ho, D.; Koo, E.; Mamalis, A.; Jagdeo, J. 2017: A Systematic Review of Light Emitting Diode (LED) Phototherapy for Treatment of Psoriasis: An Emerging Therapeutic Modality Journal of Drugs in Dermatology: Jdd 16(5): 482-488
Pariser, D.M.; Green, L.J.; Stein Gold, L.; Sugarman, J.L.; Lin, T.; Pillai, R. 2018: Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy Journal of Drugs in Dermatology: Jdd 17(7): 723-726